|ALITRETINOIN (9-cis-RETINOIC ACID)
Classifications: antiacne (retinoid); Therapeutic: antiacne
Pregnancy Category: D
Naturally occurring retinoid that binds to and activates all known retinoid receptors in cells, which regulate cellular
differentiation and proliferation in both healthy and neoplastic cells.
Inhibits the growth of Kaposi's sarcoma (KS) in HIV patients. It does not prevent the development of new KS lesions.
Treatment of cutaneous lesions of AIDS-related Kaposi's sarcoma.
Cutaneous T-cell lymphomas.
Hypersensitivity to alitretinoin or other retinoids including vitamin A; when systemic anti-KS therapy is required; pregnancy
(category D), lactation.
Cutaneous T-cell lymphoma. Safety and efficacy in children <18 y, or older adults ≥65
y, are unknown.
Route & Dosage
|Cutaneous Kaposi's Sarcoma
Adult: Topical Apply sufficient gel to cover lesions b.i.d., may increase application to 34 times daily if tolerated
- Apply gel liberally over lesions; avoid unaffected skin and mucus membranes.
- Dry 35 min before covering with clothes. Do not cover with occlusive dressing.
- Store at 15°30° C (59°86° F).
Adverse Effects (≥1%)Skin:
Erythema, edema, vesiculation, rash, burning pain,
pruritus, exfoliative dermatitis,
Increased toxicity with insect repellents containing DEET.
Assessment & Drug Effects
- Monitor for S&S of dermal toxicity (e.g., erythema, edema, vesiculation).
Patient & Family Education
- Allow up to 14 wk for therapeutic response.
- Avoid exposure of medicated skin to sunlight or sun lamps.
- Contact physician if inflammation, swelling, or blisters appear on medicated areas.